

Quasispecies composition and diversity do not reveal any predictors for chronic classical swine fever virus infection

Maria Jenckel¹ · Sandra Blome¹ · Martin Beer¹ · Dirk Höper¹

Received: 10 June 2016 / Accepted: 20 October 2016 / Published online: 24 November 2016
© Springer-Verlag Wien 2016

Abstract Classical swine fever (CSF) can run acute, chronic, and prenatal courses in both domestic pigs and wild boar. Although chronic infections are rare events, their epidemiological impact is very high due to the long-term shedding of virus. So far, little is known about the factors that influence disease course and outcome from either the host or virus's perspective. To elucidate the viral determinants, we analyzed the role of the viral populations for the development of chronic CSF virus (CSFV) infections. Three different animal trials that had led to both chronic and acute infections were chosen for a detailed analysis by deep sequencing. The three inocula represented sub-genogroups 2.1 and 2.3, and two viruses were wild-type CSFV, one derived from an infectious cDNA clone. These viruses and samples derived from acutely and chronically infected animals were subjected to next-generation sequencing. Subsequently, the derived full-length genomes were compared at both the consensus and the quasispecies level. At consensus level, no differences were observed between the parental viruses and the viruses obtained from chronically infected animals. Despite a considerable level of variability at the quasispecies level, no indications were found for any predictive pattern with regard to the chronicity of the CSFV infections. While there might be no direct marker for chronicity, moderate virulence of some CSFV strains in itself seems to be a

crucial prerequisite for the establishment of long-term infections which does not need further genetic adaptation. Thus, general host and virus factors need further investigation.

Introduction

Classical swine fever (CSF) is a viral infection of pigs with high economic impact world-wide. The causative agent is Classical swine fever virus (CSFV), a small enveloped RNA virus belonging to the genus *Pestivirus* within the family *Flaviviridae*. The genome of CSFV has a size of approximately 12.3 kb and comprises a single open reading frame (ORF) coding for one polyprotein which is co- and post-translationally processed into 12 mature proteins [1, 2]. The ORF is flanked by 5' and 3' non-translated regions (NTR). While the structural proteins (C, E1, E2, and E^{trns}) are encoded in the 5'-region of the genome, the 3'-region encodes the non-structural proteins (N^{pro}, p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B) [3, 4] with the exception of the autoprotease N^{pro} which precedes the structural proteins at the 5'-end of the ORF [5]. Classical swine fever virus strains can be assigned to three genogroups with three to four sub-genogroups each [6]. This classification is based on partial sequences, namely 150 nt of the 5'-NTR and 190 nt of the E2 encoding region [7]. Most genogroups show a distinct geographical distribution pattern [8] but there is no clear correlation between a specific genogroup and virulence. Over the last decades, moderately virulent strains of genogroup 2, especially sub-genogroups 2.1 and 2.3, have predominated in Europe and several other regions world-wide [9].

Electronic supplementary material The online version of this article (doi:10.1007/s00705-016-3161-8) contains supplementary material, which is available to authorized users.

✉ Sandra Blome
sandra.blome@fli.de

¹ Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Südufer 10, 17493 Greifswald-Insel Riems, Germany

Course and outcome of CSF can vary between acute, chronic, and prenatal forms of infection [10]. The two former are results of postnatal infection with the acute form leading to either death (acute-lethal) or convalescence (acute transient) of the infected animal, and the chronic form always being fatal [10]. Among the typical signs of acute CSF are high fever, general depression, anorexia, gastrointestinal and respiratory signs, ataxia, and hemorrhages [10]. Initial signs of chronic CSF are similar to the acute infection but generally mild. Later, predominantly non-specific signs are observed including intermittent fever, chronic enteritis and wasting. The affected animals may survive for a few months before they eventually die. The outcome of prenatal CSFV infections depends on the stage of gestation and the virulence of the CSFV strain involved [11]. While transplacental infections in early pregnancy often result in abortions and malformations, immunotolerant, persistently infected piglets can be induced when infections take place in the second or third month of gestation (mainly between days 50 and 70). This phenomenon is similar to bovine viral diarrhea virus infection and the induction of persistently infected calves [10]. Affected animals are reported to eventually die from the so-called “late-onset” form of CSF. Recently, it has been demonstrated that a persistence/immunotolerance phenomenon can also be induced in suckling piglets very early after farrowing [12, 13]. Both, the animals displaying the postnatally acquired chronic form of CSFV and the persistently infected animals constantly shed large amounts of virus and are therefore important reservoirs and sources of CSFV. However, it is important to note that persistent infection is a tolerance phenomenon while chronic infections result from an impaired but existent immune response. While the acute courses of the disease have been extensively studied, research into the epidemiologically important chronic infection (here defined as postnatal infection for at least 28 days with constant shedding of virus and no or little antibody response) is hampered by its rare occurrence under experimental conditions. Hence, little is known about host and viral factors favoring the chronic course. Known factors influencing course and outcome of CSFV infection include age and immune status of the host as well as the virulence of the CSFV strain involved [10]. The chronic course of disease is mainly seen after infection with moderately virulent CSFV strains and is characterized by a prolonged period (at least 28 days) of unspecific signs (intermittent fever, chronic enteritis, wasting) and constant shedding of virus [10]. Antibodies may temporarily be present at low titers; however, the host’s immune system seems to be unable to mount an effective immune response. Recently, it has been demonstrated that chronically infected animals show an up-regulation of genes that can inhibit NF- κ B- and IRF3/7-

mediated transcription of type I interferons [14]. Moreover, activation of natural killer and cytotoxic T-cell pathways seem to be impaired [14]. In addition, it has been shown that genes related to the human autoimmune disease systemic lupus erythematosus were upregulated in animals suffering from chronic disease [14]. The latter findings support the assumption that chronic CSF has a strong immune-pathological aspect. Very little is known about the impact of CSFV genetics and genetic adaptations during the infection process on the manifestation of a chronic disease and in this respect, links between viral gene function (e.g. inhibition of interferon responses or apoptosis inhibition) are scarce. Given the high viral replication in chronic infection, a high degree of genetic plasticity was anticipated, at least similar to that of persistently infected cattle [15–17].

Here, we studied the possible influence of the viral genome and its quasispecies composition on the course of CSF. Based on the finding that viruses re-isolated from a chronically infected animal did not indicate an impact of the virus and its quasispecies, additional samples were selected from animal trials performed with different CSFV strains which had led to acute and chronic courses in different animals. These samples were subjected to full-genome virus deep-sequencing. The resulting sequences of the inocula and viruses found in acutely or chronically infected animals were compared at the consensus sequence and at the quasispecies level. It has to be noted that chronic disease courses cannot be reliably induced and that none of the initial trials were conducted to study chronic CSF infections. Thus, only the remaining, sometimes sub-optimal materials of a few individual animals could be investigated over time (the total of samples available to the authors). However, the samples at hand still provided the opportunity to get an orientating dataset that was, to date, missing.

Materials and Methods

Samples, RNA extraction, library preparation, and sequencing

Samples were selected from previously conducted and published animal trials [18–21] that had led to the occurrence of chronically infected animals (clinical, virological and serological responses of the included animals are summarized in supplementary table S1). Depending on the availability of suitable blood and leukocyte samples, acute and chronic disease courses were compared at virus level. Details of samples subjected to next-generation sequencing (NGS) are presented in Table 1. All inocula used for the animal trials were sequenced and sample preparation and

Table 1 Summary of sample materials and obtained sequencing results

Sample ID ¹	Trial	Animal	Animal #	Virus	sample matrix ²	Sampling dpi	Disease course	Sequence	Accession
T1-inoculum	1	NA	NA	Alfort-p447	CCS	NA	NA	complete coding	LT593760
T1-DP43C7L	1	Domestic pig	43	Alfort-p447	leukocytes	7	chronic	NA	NA
T1-DP43C10L	1	Domestic pig	43	Alfort-p447	leukocytes	10	chronic	complete coding	LT593748
T1-DP43C44S	1	Domestic pig	43	Alfort-p447	serum	44	chronic	complete coding	LT593754
T1-DP44AT10L	1	Domestic pig	44	Alfort-p447	leukocytes	10	acute-transient	NA	NA
T2-inoculum	2	NA	NA	CSF1047	CCS, 4 th passage	NA	NA	complete coding	LT593753
T2-CSFV1047-P5	2	NA	NA	CSF1047	CCS, 5 th passage	NA	NA	complete coding	LT593759
T2-DP365C10B	2	Domestic pig	365	CSF1047	EDTA blood	10	chronic	complete coding	LT593762
T2-DP365C41B	2	Domestic pig	365	CSF1047	EDTA blood	41	chronic	complete coding	LT593756
T2-DP366C10B	2	Domestic pig	366	CSF1047	EDTA blood	10	chronic	complete coding	LT593761
T2-DP366C41B	2	Domestic pig	366	CSF1047	EDTA blood	41	chronic	complete coding	LT593755
T2-DP368AL14B	2	Domestic pig	368	CSF1047	EDTA blood	14	acute-lethal	complete coding	LT593752
T3-inoculum	3	NA	NA	CSF1045	CCS	NA	NA	complete coding	LT593749
T3-DP56AT3L	3	Domestic pig	56	CSF1045	Leukocytes	3	acute-transient	NA	NA
T3-DP56AT14L	3	Domestic pig	56	CSF1045	Leukocytes	14	acute-transient	NA	NA
T3-DP60AL3L	3	Domestic pig	60	CSF1045	Leukocytes	3	acute-lethal	NA	NA
T3-DP60AL7L	3	Domestic pig	60	CSF1045	Leukocytes	7	acute-lethal	NA	NA
T3-WB13AT3L	3	Wild boar	13	CSF1045	Leukocytes	3	acute-transient	NA	NA
T3-WB13AT14L	3	Wild boar	13	CSF1045	Leukocytes	14	acute-transient	NA	NA
T3-WB15C3L	3	Wild boar	15	CSF1045	Leukocytes	3	chronic	NA	NA
T3-WB15C14L	3	Wild boar	15	CSF1045	Leukocytes	14	chronic	complete coding	LT593750
T3-WB16AL3L	3	Wild boar	16	CSF1045	Leukocytes	3	acute-lethal	NA	NA
T3-WB16AL14L	3	Wild boar	16	CSF1045	Leukocytes	14	acute-lethal	complete coding	LT593757
T3-DP49AL3L	3	Domestic pig	49	CSF1045	Leukocytes	3	acute-lethal	NA	NA
T3-DP49AL14L	3	Domestic pig	49	CSF1045	Leukocytes	14	acute-lethal	complete coding	LT593758
T3-DP53AL3L	3	Domestic pig	53	CSF1045	Leukocytes	3	acute-lethal	NA	NA
T3-DP53AL14L	3	Domestic pig	53	CSF1045	Leukocytes	14	acute-lethal	complete coding	LT593751

¹ notation of the sample IDs: Tx, animal trial number; animal race and number (DP, domestic pig; WB, wild boar); course of infection (C, chronic; AT, acute-transient; AL, acute-lethal); sampling time point (dpi); sample matrix (L, leukocytes; B, blood; S, serum)

² CCS - cell culture supernatant

sequencing of the inocula was done as described below for the samples derived from the respective animal trials. From all samples, total RNA was extracted with Trizol Reagent (Invitrogen, Carlsbad, USA) in combination with RNeasy columns (Qiagen, Hilden, Germany) including on-column DNase I digestion, as recommended by the manufacturer. RNA was converted to double stranded DNA using the cDNA synthesis kit (Roche, Mannheim, Germany) as described in the Genome Sequencer Rapid RNA library preparation guide (Roche).

Animal trial 1: In this trial, a group of five weaner pigs (about 6 weeks of age) was intranasally and intramuscularly inoculated with 10^6 tissue culture infectious doses 50 % (TCID₅₀) of the moderately virulent CSFV “Alfort-p447” (genotype 2.3) derived from an infectious cDNA clone, as previously described [19]. One animal (#43) showed a chronic CSFV infection, and samples of days 10 and 44 post infection were subjected to NGS. In addition, sequencing was attempted from a sample of an acute-transiently infected animal taken at 10 days post infection (dpi). Despite the limited availability of sample material, this trial was used as a proof-of-principle approach. Samples were prepared for pyrosequencing, as previously described [22]. Sequencing was conducted on the Genome Sequencer FLX (Roche) with Titanium chemistry (Roche) according to the manufacturer’s instructions.

Animal trial 2: In this vaccination/challenge trial, a control group of four domestic weaner pigs (6–8 weeks of age) were oro-nasally inoculated with 3.6×10^5 TCID₅₀ of the 4th passage of moderately virulent, genotype 2.1 CSFV isolate “CSFV1047” [20], isolated in Israel in 2009 [21]. Samples taken at 10 and 41 dpi from two animals, which developed a chronic infection, were subjected to NGS. These samples were supplemented with a sample originating from a pig showing the acute-lethal course of CSFV (taken 14 dpi). Unfortunately, sufficient sample material of the original inoculum was not available for all tests. Therefore, the 5th passage was also sequenced to serve as the substitute inoculum dataset, however, since this showed three consensus substitutions compared to the 4th passage, it was used as an individual sample. Sequencing libraries were prepared using the Nextera XT kit (Illumina, San Diego, USA) according to manufacturer’s instructions except for T2-inoculum and T2-CSFV1047-P5 which were prepared as previously described [23]. Additionally, T2-CSFV1047-P5 was amplified over 12 cycles. Sequencing was done with the Illumina MiSeq (Illumina).

Animal trial 3: The corresponding samples were collected during a host response trial [18] with pigs of different breeds (German landrace pigs (12 weeks of age), hybrid pigs (8–10 weeks of age), European wild boar (12 weeks of age)) which were oro-nasally inoculated with $10^{5.5}$ TCID₅₀ of the moderately virulent, genotype 2.3

CSFV strain “Roesrath” (isolated in Germany 2009 [24]). One wild boar became chronically infected, and samples from days 3 and 14 post infection were used for NGS. In addition to the samples from the chronically infected animal, four samples from animals with the acute-lethal disease course (three domestic pigs of different breeds and one wild boar), and two from transiently infected animals (one domestic pig, one wild boar) were sequenced. Sequencing libraries were prepared as previously described [23] and amplified after library preparation using Nextflex primer (Biooscientific, Austin, USA) and AccuPrime Polymerase (Invitrogen) for 15 cycles. Library T3-inoculum was initially prepared for pyrosequencing as described above (animal trial 1) and subsequently converted into an Illumina compatible library using the Nextera XT kit, as per the manufacturer’s recommendations. Sequencing was done with the Illumina MiSeq (Illumina).

Sequence data analysis

Consensus sequences were assembled from the raw data using the Genome Sequencer software suite (v. 2.6; Roche). To this end, raw reads originating from CSFV RNA were identified by mapping (Genome Sequencer software suite v2.6) the complete datasets against all available CSFV sequences in Genbank, and mapped reads were subsequently used for *de novo* assembly. In case of data originating from animal trial 2, only partial datasets were used for the initial *de novo* assembly of complete genome sequences. Finally, to eliminate assembly errors, all raw sequence reads were mapped against the resulting consensus sequences. To compare consensus sequences of complete coding regions, these were aligned using MAFFT [25] within Geneious 8.0.5 (Biomatters Ltd, Auckland, New Zealand).

Population analyses

Quality trimming and duplicate reads removal were performed prior to population analysis using the QUASR pipeline [26] with $-l$ 50 and $-m$ 30 for minimum length and minimum mean read quality, respectively to remove PCR artifacts. For population analysis, the procedure previously described [27] was further developed. In brief, ten equalized read datasets of each sample resulting in an average depth of 500x or 250x for T2 and T3, respectively, were mapped (Genome Sequencer software suite v3.0; Roche) along the respective inoculum consensus genome (forward and reverse) and a detailed 454AlignmentInfo.tsv file was generated using the $-nft$ parameter. All subsequent calculations were performed in R [28]. From the data in file 454AlignmentInfo.tsv, proportions were calculated for every base at every position. For high

reliability of the results, only variants with frequencies of at least 0.05 were taken into account when the frequencies between the forward and reverse mapping results did not differ more than 4-fold. Again, this was done to exclude variants which were possibly introduced by PCR bias. For the calculation of Manhattan distances between viral populations, 500 bootstrap replicates were calculated from the complete table representing the frequencies of all bases at all genome positions. Finally, the mean distances of the bootstraps were calculated for each partial read dataset. For plotting, the Manhattan distances were fitted 2-dimensionally using R function `cmdscales`. For the final plot, the focus of the population locations for each sample was calculated.

Results

For 12 out of a total of 26 samples, derived from 3 different animal trials with different breeds and disease courses, sufficient raw reads were obtained for the assembly of complete genome sequences. In general, the generation of sufficient raw data for consensus genome sequence assembly was possible from the inocula and from samples derived from animals after infection of at least 10 days, more readily for chronically than from acutely infected animals. Moreover, for the samples from animal trials 2 and 3, the raw data also enabled single nucleotide variant (SNV) analyses at the population level.

Prolonged viral replication in chronically infected animals does not give rise to consensus sequence alterations

As a starting point, and to get an impression of the major changes within the viral genomes, raw sequence reads were assembled into consensus sequences comprising at least the complete coding sequences. Regardless of the disease course, comparison of these sequences uncovered no (animal trials 1 and 3) marked differences between sequences determined for the viruses from inocula and those derived from animal samples.

From animal trial 1, two out of the available four samples yielded sufficient raw data. Besides the inoculum (T1-inoculum) for two samples drawn from one chronically infected animal at two time points (T1-DP43C10L and T1-DP43C44S), the obtained data were sufficient for the analysis of the complete coding sequences. Comparison of the available consensus sequences for these samples showed no differences for the complete genome. The sample collected from an acute-transiently infected animal did not contain enough viral RNA to warrant sequencing of the viral genome.

All samples collected from animal trial 2 contained high viral loads that enabled complete genome sequencing. Like in animal trials 1 and 3 (see next paragraph), analyses of the viral genome sequences derived from the samples drawn from two chronically infected animals (T2-DP365C10B, T2-DP365C41B, T2-DP366C10B, and T2-DP366C41B) revealed no differences at the consensus sequence level in comparison with the sequence determined for the inoculum (T2-inoculum). However, in contrast to trial 3, the comparison of the consensus sequence of the sample taken from an acute-lethally infected pig (T2-DP368AL14B) with the consensus sequence of the inoculum (T2-inoculum) unveiled 4 single base substitutions (A3245C, T3381C, C3724A and C8955T), 2 of which were synonymous and 2 non-synonymous. Notably, one synonymous and one non-synonymous substitution occurred within the genetically very stable p7-encoding region. Since the available material from the inoculum of animal trial 2 only permitted sequencing to a median depth of not more than 33, we attempted to add depth by sequencing the 5th passage of this isolate (T2-CSFV1047-P5; one cell culture passage from the initial virus). However, the comparison of the consensus sequences obtained for the 4th and 5th passages revealed three differences in the sequences, namely T1428A, T3603C, and A8934T. Of these, T1428A is non-synonymous causing the amino acid substitution S476R within the E^{ms} protein which is a known cell culture adaptation enabling heparan sulfate binding [29]. Due to the aforementioned changes, the dataset for the inoculum remained unchanged.

For four out of fourteen samples that were available from animal trial 3, sequencing yielded sufficient raw data for full-genome analysis. Like in the other two animal trials, comparison of the consensus sequences obtained from the sample of the chronically infected animal (T3-WB15C14L) uncovered no differences. Unlike sample T2-DP368AL14B, comparison of the consensus sequences obtained for the acute-lethally infected animals (T3-WB16AL14L, T3-DP49AL14L, and T3-DP53AL14L) also uncovered no deviations from the inoculum (T3-inoculum) sequence.

Population analyses uncovers differences in virus evolution between different trials and inocula

For a more detailed insight, we performed viral population analyses. To achieve a high resolution in determining the viral relations we analyzed the population data according to an approach previously described [27] and similarly also applied elsewhere [30]. This analysis takes the frequencies of all detected single nucleotide variants (SNV) into account to calculate distances between populations. This

calculation was only possible for animal trials 2 and 3, since for animal trial 1 the sequence depth was not sufficient and no additional sample material was available for additional sequencing. The results of the population-based distance and diversity analyses are summarized in Figure 1.

The viral population of T2-inoculum had certain diversity, as reflected by the spot size in Figure 1A. Regarding the chronically infected animals, the viral diversity clearly increased only in animal DP366 after 41 days (T2-DP366C41B), and stayed relatively constant in the other samples. In comparison with the inoculum, the viral population drawn from the acute-lethally infected animal (DP368) had also diversified (T2-DP368AL14B). The overall topology of the plot (Figure 1A) implies that in all animals a similar portion of the initial viral population was selected since all populations shifted in the same direction from the inoculum although with different distances. On the contrary, the population of the 5th cell culture passage (T2-CSFV1047-P5) of the original virus isolate shifted in the opposite direction, implying that a different subpopulation of the original strain had further adapted to cell culture. This is in concordance with the consensus sequence analysis. The viral populations of the samples derived from individual chronically infected animals were closely related to each other. In both cases, the viral populations found in samples drawn from the chronically infected animals after 41 dpi moved slightly back in the direction of the inoculum, i.e. they had a slightly higher similarity with the inoculum than did the samples taken after 10 dpi. The population of the acute-lethally infected animal substantially deviated from all populations derived from chronically infected animals. Nevertheless, it was more related to the samples after animal passage than with the inoculum and its 5th cell culture passage.

In contrast to animal trial 2, the diversity and distance analysis of the data available for trial 3 revealed lower distances between the populations although this was accompanied by similar diverse populations as detected in animal trial 2. Figure 1B depicts the results of this analysis for animal trial 3 at the same scale as Figure 1A for animal trial 2. In the enlarged plot (Figure 1C) of the distance and diversity analysis for trial 3 it is visible that the diversity initially present in the inoculum in trial 3 had substantially increased after the animal passages. Moreover, while the analysis of animal trial 2 unveiled that the same portion of the population of the inoculum was selected (as visualized by the concurrent shift of the spots of the animal samples) and further diversified, there is no direction visible in the graph for animal trial 3. Rather, the inoculum is located centrally among the populations drawn from the animals.

Detailed analyses of the viral populations fit distance and diversity analyses and provide functional clues to detected variants


Although the sequencing depth for the inoculum in animal trial 2 (T2-inoculum) was less than that for the other samples, the variants detected in the population appear to be reliable. This is implied by the concordance between the variable positions detected in the populations of both the inoculum (T2-inoculum) and its subsequent passage (T2-CSFV1047-P5), albeit at different frequencies (table 2, e.g. 1428, 3603, 8934). Moreover, the presence of variants at the same positions in the populations derived from animal samples strengthens this assumption.

A closer look at the detected SNVs supports the implication of the distance and diversity analyses that in animal trial 2 a selection against cell culture adaptations of the inoculum population took place. Some examples for this selection are provided in the following: First of all, the frequencies of the three variants that were detected in the inoculum (Table 2; T2-inoculum; 1428A, 3603C, 8934T, with frequencies of roughly 0.4) were clearly reduced after the animal passages, but were enhanced to frequencies of approximately 0.8 in the subsequent cell culture passage (T2-CSFV1047-P5). Although all three were detected with clearly reduced frequencies in the animal samples, one (1428A) of these was still present in all viral populations after animal passage, but the other two (3603C, 8934T) were absent from the population sampled in the acute-lethally infected animal. Although variant 2317A (Table 2) was not detected in T2-inoculum, it was present in all animal derived populations. Secondly, most variants detected in the populations from chronically infected animals occurred in a pairwise manner, i.e. a variant that was present at 10 dpi was also present at 41 dpi, as was the variant at position 3192 in animal DP366 (Table 2; T2-DP366C10B, T2-DP366C41B). Conversely, those variants that were absent from one of the populations were not detected in the corresponding sample as well (see variants at position 3192 in animal DP365). Thirdly, a substantial number of variants occurred exclusively in the viral population of the acute-lethally infected animal DP368 (Table 2; T2-DP368AL14B). Four of these variants (3245C, 3381C, 3724A, 8955T) were found with a constant frequency of roughly 0.75. These determine the consensus and contribute substantially to the distance of the respective population from all other populations. The exclusive differences are the basis for the clear separation of DP368 from the virus populations derived from the chronically infected animals.

In the samples collected in animal trial 3, a different situation was observed. On the one hand, no samples drawn from the same animal at different times were available,

Fig. 1 Metrically scaled Manhattan distances between viral populations. The sizes of the circles represent the diversity of the viral populations (solid, mean variability calculated from the replicates; dashed, mean plus standard deviation). For details about calculations please refer to materials and methods.

(A) Viral populations of animal trial 2 (T2). For T2-inoculum no standard deviation could be calculated since the data were not sufficient for replicate calculations based on partial datasets. (B) Viral populations of animal trial 3 (T3) plotted with the same scale as (A). The dotted rectangle shows the region that is enlarged in (C). (C) Enlarged plot of viral populations of T3



rendering the correlation of variant frequencies over time impossible. On the other hand, more variants were present in the inoculum population, albeit at lower frequencies. These variants were all maintained in the viral populations in all but one of the animal samples (Table 3; variant 1957A was absent from the population in sample T3-DP53AL14L).

The scattering of the populations in variable directions and distances from the inoculum can be explained by the occurrence of different variants which are mainly found in individual samples. Four exceptions from this observation were detected (Table 3; 472A/472C, 2655C/2655G, 7032G, 8455T). Of note, at nucleotide 472, the two different variants 472A and 472C were detected in a background of 472T in samples T3-WB16AL14L and T3-DP53AL14L, respectively.

Both in animal trials 2 and 3, a number of non-synonymous variants were detected within the viral populations (Tables 2 and 3). In trial 2 at four positions and in trial 3 at five positions 6 non-synonymous variants were detected. The density of non-synonymous variants was higher in the regions encoding proteins for direct interaction between virus and host, i.e. the surface proteins of the virus. In virus populations derived from animal trial 2, two

of the four non-synonymous variants were located in non-structural protein encoding regions, namely in the p7 and in the NS2 encoding regions. The other 2 non-synonymous variants were located in the E^{ns} and the E2 encoding regions, both known as antibody targets. In the populations analyzed from animals of trial 3, three out of six non-synonymous SNVs were located in genomic regions encoding non-structural proteins. Two of these were different variants at the same position in the N^{pro} coding region. Another non-synonymous SNV in samples T3-WB16AL14L and T3-DP49AL14L was located in the NS4B encoding region. One of the other 3 non-synonymous SNVs was located within the E^{ns} and the remaining 2 non-synonymous SNVs were in the E1 encoding regions, respectively.

Discussion

Chronically infected animals are among the crucial factors impacting on disease transmission and perpetuation of long-term outbreaks. While their role might be limited in outbreak scenarios, under modern industrialized settings with a stamping out policy, they gain importance in

Table 2 Summary of variants detected in the populations of samples derived from animal trial 2, mean percentages and standard deviations

Base ¹ Amino acid ²	Protein Domain	T2-inoculum 4P	T2-CSFV1047- P5	T2- DP365C10B ³	T2- DP365C41B ³	T2- DP366C10B	T2- DP366C41B ³	T2- DP368AL14B ³
870A 290R	E ^{ms} RNase T2	100	100 ± 0	100 ± 0	100 ± 0 (96.6 ± 1.4)	99.4 ± 1.8	90.5 ± 1.8	100 ± 0
870G		0	0 ± 0	0 ± 0	0 ± 0 (3.7 ± 0.9)	5.7 ± 0	9.2 ± 1.6	0 ± 0
1428A 476R	E ^{ms}	37.5	82.7 ± 1.1	0 ± 0 (2.6 ± 0.5)	10.4 ± 1.3	6.4 ± 1.2	15.4 ± 2.2	0 ± 0 (2.2 ± 0)
1428T 476S		62.5	17.3 ± 1.1	100 ± 0 (98.3 ± 0.9)	89.3 ± 1.2	96.2 ± 3.4	83.9 ± 2.1	100 ± 0 (99.3 ± 0.9)
2259A 753R	E2 Antigenic Unit B/C	0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	12.2 ± 1.4
2259G		100	100 ± 0	100 ± 0	100 ± 0	100 ± 0	100 ± 0	87.7 ± 1.4
2317A 773I	E2 Antigenic Unit B/C, AVD	0	0 ± 0	6.2 ± 0	0 ± 0 (3.2 ± 0.7)	5.9 ± 0.6	0 ± 0 (2.7 ± 0.6)	5.4 ± 0.2
2317T 773F		100	100 ± 0	99.4 ± 2.0	100 ± 0	97.7 ± 3.0	100 ± 0	98.9 ± 2.3
3192A 1064Q	p7	0	0 ± 0	0 ± 0	0 ± 0 (97.3 ± 1.6)	21.1 ± 3.4	14.2 ± 1.8	0 ± 0
3192G		100	100 ± 0	100 ± 0	100 ± 0	78.9 ± 3.4	85.8 ± 1.8	100 ± 0
3245A 1082N	p7	100	100 ± 0	100 ± 0	100 ± 0	100 ± 0	100 ± 0	22.7 ± 2.4
3245C 1082T		0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	77.2 ± 2.6
3261C 1087Y	p7	100	100 ± 0	100 ± 0	100 ± 0 (99.3 ± 0.7)	77.2 ± 3.9	84.3 ± 2.1	86.4 ± 1.8
3261T		0	0 ± 0	0 ± 0	0 ± 0 (1.6 ± 0)	22.4 ± 3.9	15.5 ± 2.1	13.2 ± 1.8
3381C 1094Q	p7	0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	74.9 ± 1.3
3381T		100	100 ± 0	100 ± 0	100 ± 0	100 ± 0	100 ± 0	25 ± 1.3
3603C 1201A	NS2 transmembrane domain	40	83.0 ± 1.0	5.4 ± 0	12.6 ± 2.5	6.9 ± 0.8	15.9 ± 2.7	0 ± 0
3603T		60	17.0 ± 1.0	99.5 ± 1.7	87.3 ± 2.5	97.0 ± 3.5	84.1 ± 2.7	100 ± 0
3720A 1240L	NS2	100	100 ± 0	74.8 ± 1.4	79.6 ± 1.6	100 ± 0	100 ± 0	95.5 ± 3.1
3720G		0	0 ± 0	25.2 ± 1.4	20.3 ± 1.6	0 ± 0	0 ± 0	6.3 ± 0.5
3724A 1242M	NS2	0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	74.7 ± 3.0
3724C 1242L		100	100 ± 0	100 ± 0	100 ± 0	100 ± 0	100 ± 0	25.3 ± 3.0
4281C 1427V	NS2	0	0 ± 0	0 ± 0	0 ± 0	21.7 ± 2.1	14.6 ± 1.4	0 ± 0
4281T		100	100 ± 0	100 ± 0	100 ± 0	78.3 ± 2.1	85.2 ± 1.5	100 ± 0
4362A 1454V	NS2 Peptidase C74	0	0 ± 0	0 ± 0	0 ± 0	5.7 ± 0.6	5.2 ± 0.3	0 ± 0
4362G		100	100 ± 0	100 ± 0	100 ± 0	98.3 ± 2.8	99.0 ± 2.2	100 ± 0

Table 2 continued

Base ¹ Amino acid ²	Protein Domain	T2-inoculum 4P	T2-CSFV1047- P5	T2- DP365C10B ³	T2- DP365C41B ³	T2- DP366C10B	T2- DP366C41B ³	T2- DP368AL14B ³
5517G	NS3	100	100 ± 0	80.6 ± 2.5	84.2 ± 2.0	100 ± 0	100 ± 0	100 ± 0
5517T	Helicase ATP-binding	0	0 ± 0	18.8 ± 2.1	15.5 ± 1.9	0 ± 0	0 ± 0	0 ± 0
5517A		0	0 ± 0	<i>(1.7 ± 0)</i>	0 ± 0	0 ± 0	0 ± 0	0 ± 0
5565C	NS3	0	0 ± 0	0 ± 0	0 ± 0	21.5 ± 2.3	22.0 ± 1.7	0 ± 0
5565T	Helicase ATP-binding	100	100 ± 0	100 ± 0	100 ± 0	78.3 ± 2.4	77.9 ± 1.7	100 ± 0
7755C	NS4B	0	0 ± 0	6.7 ± 0.9	6.1 ± 0.6	0 ± 0	0 ± 0	0 ± 0
7755T		100	100 ± 0	96.7 ± 3.6	96.4 ± 3.1	100 ± 0	100 ± 0	100 ± 0
8307C	NS5A	0	0 ± 0	0 ± 0	0 ± 0	6.1 ± 0.7	0 ± 0	0 ± 0
8307T		100	100 ± 0	100 ± 0	100 ± 0	97.6 ± 3.2	99.5 ± 1.7 <i>(3.2 ± 0.8)</i>	100 ± 0
8934A	NS5A	57.1	14.8 ± 1.7	98.9 ± 2.2	89.0 ± 1.9	95.7 ± 3.0	84.2 ± 2.0	100 ± 0
8934T		42.9	84.5 ± 1.5	5.3 ± 0	10.6 ± 1.8	5.9 ± 0.8	15.6 ± 2.1	0 ± 0
8955C	NS5A	100	100 ± 0	100 ± 0	100 ± 0	100 ± 0	100 ± 0	22.3 ± 2.1
8955T		0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	77.5 ± 2.2
8979A	NS5A	0	0 ± 0	0 ± 0	0 ± 0	21 ± 3.0	20.4 ± 1.1	0 ± 0
8979G		100	100 ± 0	100 ± 0	100 ± 0	79 ± 3.0	79.5 ± 1.1	100 ± 0
9972A	NS5B	100	100 ± 0	100 ± 0	100 ± 0	100 ± 0	100 ± 0	95.5 ± 3.2
9972G		0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	0 ± 0	6.4 ± 1.2

¹ relative to the open reading frame

² relative to the polyprotein

³ Numbers in italics and brackets represent frequencies detected without application of the stringent parameters

Table 3 Summary of variants detected in the populations of samples derived from animal trial 3, mean percentages and standard deviations

Base ¹	Amino acid ²	Protein	Domain	T3-inoculum	T3-WB15C14L	T3-WB16AL14L	T3-DP49AL14L	T3-DP53AL14L
472A	158I	N ^{pro}	Peptidase C53	0 ± 0	0 ± 0	6.2 ± 0.5	0 ± 0	0 ± 0
472C	158L			0 ± 0	0 ± 0	0 ± 0	0 ± 0	6.7 ± 0.9
472T	158F			100 ± 0	100 ± 0	96.0 ± 3.6	100 ± 0	97.5 ± 3.3
1088G	363R	E ^{ns}		100 ± 0	100 ± 0	97.3 ± 3.6	100 ± 0	100 ± 0
1088T	363M			0 ± 0	0 ± 0	6.6 ± 0.3	0 ± 0	0 ± 0
1508A	503K	E1		0 ± 0	6.0 ± 0.5	0 ± 0	0 ± 0	0 ± 0
1508G	503R			100 ± 0	95.1 ± 2.6	100 ± 0	100 ± 0	100 ± 0
1665C	555S	E1		7.9 ± 0.3	6.1 ± 1.3	6.9 ± 1.9	6.5 ± 1.2	11.0 ± 3.9
1665T				92.5 ± 0.6	97.6 ± 3.2	95.8 ± 4.0	93.9 ± 2.6	90.1 ± 5.0
1671C	557V	E1		16.1 ± 1.0	8.7 ± 1.9	22.8 ± 4.5	15.9 ± 3.2	20.2 ± 4.1
1671T				83.9 ± 1.0	91.3 ± 1.9	77.2 ± 4.5	84.1 ± 3.2	79.8 ± 4.1
1957A	653I	E1		6.7 ± 0.7	11.9 ± 2.8	12.8 ± 2.2	6.2 ± 1.0	0 ± 0
1957G	653V			94.0 ± 2.2	88.1 ± 2.8	87.0 ± 2.2	95.7 ± 3.1	100 ± 0
2422C	808L	E2	antigenic unit A/D	0 ± 0	0 ± 0	0 ± 0	6.1 ± 0.7	0 ± 0
2422T				100 ± 0	100 ± 0	100 ± 0	95.4 ± 2.7	100 ± 0
2655C	885Y	E2		0 ± 0	0 ± 0	0 ± 0	0 ± 0	7.1 ± 1.5
2655G	885*			0 ± 0	0 ± 0	5.4 ± 0.2	0 ± 0	0 ± 0
2655T	885Y			100 ± 0	100 ± 0	98.4 ± 2.6	100 ± 0	94.9 ± 3.7
3534A	1178A	NS2		84.2 ± 2.1	86.0 ± 3.2	75.5 ± 3.8	83.3 ± 3.3	78.0 ± 4.5
3534G				15.8 ± 2.1	13.7 ± 3.2	24.0 ± 4.1	16.7 ± 3.3	21.7 ± 4.2
5800A	1934R	NS3	Helicase ATP-binding	0 ± 0	0 ± 0	11.3 ± 2.5	0 ± 0	0 ± 0
5800C				100 ± 0	100 ± 0	88.7 ± 2.5	100 ± 0	100 ± 0
6270A	2090A	NS3	Helicase C-terminal	0 ± 0	0 ± 0	0 ± 0	0 ± 0	7.0 ± 2.0
6270T				100 ± 0	100 ± 0	100 ± 0	100 ± 0	95.2 ± 4.6
7032G	2344W	NS4B		0 ± 0	0 ± 0	5.2 ± 0	5.4 ± 0.2	0 ± 0
7032T	2344C			100 ± 0	100 ± 0	99.5 ± 1.6	96.7 ± 2.9	99.5 ± 1.6
7419C	2473F	NS4B		71.9 ± 3.5	69.8 ± 4.5	56.1 ± 4.8	62.1 ± 4.5	59.0 ± 6.2
7419T				28.1 ± 3.5	30.2 ± 4.5	43.8 ± 4.8	37.0 ± 4.3	41.0 ± 6.2
8028C	2676S	NS4B		0 ± 0	5.7 ± 0.8	5.8 ± 0	0 ± 0	5.5 ± 0.6
8028T				100 ± 0	95.1 ± 3.6	96.0 ± 3.1	98.9 ± 2.4	96.8 ± 3.5
8445C	2815N	NS5A	glycosylation site	100 ± 0	96.5 ± 3.1	100 ± 0	99.4 ± 2.0	99.0 ± 3.1
8445T				0 ± 0	5.4 ± 0	0 ± 0	0 ± 0	9.7 ± 0
9288A	3096L	NS5A		0 ± 0	0 ± 0	0 ± 0	0 ± 0	7.3 ± 0.9
9288G				100 ± 0	100 ± 0	100 ± 0	100 ± 0	96.4 ± 3.9
9378C	3126F	NS5A		84.0 ± 1.2	88.2 ± 2.6	78.5 ± 3.3	86.9 ± 4.1	78.9 ± 3.7
9378T				16.0 ± 1.2	11.8 ± 2.6	21.4 ± 3.2	13.0 ± 3.9	21.1 ± 3.7
9933A	3311R	NS5B		11.0 ± 1.2	10.4 ± 1.6	9.5 ± 2.5	7.5 ± 2.0	6.0 ± 0.2
9933G				89.0 ± 1.2	89.3 ± 1.7	90.4 ± 2.3	93.4 ± 2.9	98.5 ± 2.5
10476A	3492V	NS5B		0 ± 0	0 ± 0	5.9 ± 0.9	0 ± 0	0 ± 0
10476C				100 ± 0	100 ± 0	97.0 ± 3.2	100 ± 0	100 ± 0

¹ relative to the open reading frame² relative to the polypeptide

endemically infected countries and wild boar populations. In the latter, chronic and persistent infections are probably the most important drivers of long-term persistence of CSFV in a wild boar population [31] and harbor the threat of reintroducing CSFV into naïve populations.

The factors influencing the development of chronic infections are still far from being understood although chronicity seems to be linked to the moderate virulence of the CSFV strain involved [14]. One reason for the lack of data is the rare and rather unpredictable occurrence of

chronically infected animals under experimental conditions and the limited availability of comparable sample sets. In the present study, we collected samples from different animal trials that had given rise to acute and chronic infections and accepted the diversity of sample matrices, viral load, and background. None of the studies was performed to investigate chronic infections and thus, remaining and sometimes suboptimal samples had to be employed.

Essentially, we tested the hypothesis that chronic infections could result from changes in the viral consensus sequence and/or a higher viral diversity and thus (partial) immune escape and continued high-level replication.

However, our results do not support this hypothesis. Even under the condition of chronic infection, CSFV is surprisingly stable at both the consensus and the quasispecies level contrasting with other infections, e.g. persistent BVDV [17]. High stability was shown in different settings with both field-type viruses with expected viral quasispecies, and viruses derived from a cDNA clone with lower quasispecies diversity. Single base substitutions were only observed for one acute-lethally infected animal showing two synonymous and two non-synonymous substitutions. Interestingly, two of these substitutions (one of them non-synonymous) occurred in the p7-encoding region. This contrasts findings with similar strains under field conditions, where this region was completely stable for the same strain over years [32]. The fact that the known cell culture adaptive E^{ns} mutation was found in the 5th passage of CSFV “Roesrath” adds reliability to the analyses and can act as a positive control.

Subsequent population analyses also did not reveal any marked differences between acute-lethally and chronically infected animals. However, an accordant drift was observed for all animal-derived samples in trial 2, and the virus population from both one chronically and one acute-lethally infected animal showed an increased diversity. In trial 3, viral sequence diversity increased but distances were smaller. Again, no differences were seen among disease courses. Thus, also the direction and extent of genetic changes did not indicate factors favoring chronicity.

Detailed analyses of SNV of samples from trial 2 suggest that the observed changes (the observed drift) were mainly selections against cell culture adaption. This assumption is strengthened by the fact that the further passaged virus (until passage 5) shows mutations in the opposite direction and that these selections are missing in trial 3 where a virus was used that showed a field-type phenotype, both at the sequence level and in *in vitro* experiments [33, 34]. Furthermore, this virus showed a higher quasispecies diversity, as is expected for a successful field virus infection.

Yet, the high overall stability and rather low diversity under selective pressure and high replication is surprising as the existence of a broad quasispecies has often been discussed as a virulence and robustness factor [35]. Moreover, reduced quasispecies diversity was shown to result in virus attenuation [36]. An explanation could be that most variants were non-functional or disadvantageous for virus replication and therefore remained at low frequency. This would be in line with recent studies that showed that a majority of virus variants are non-functional [37]. Furthermore, it could be shown that highly virulent CSFV clones could be generated based on only the consensus sequence [38].

Based on the limited data set that was available for analyses, it can be stated:

- CSFV seems exceptionally stable even under conditions of chronic infection with high and continued viral replication,
- No marked differences in the viral genomes were observed between an acute-lethal and a chronic infection with the same CSFV strain.
- The disease courses seem to be independent of the viral quasispecies (no predictors for chronicity),
- Host factors and virus host interactions need further investigation, preferably targeting a larger and more consistent data set.

Acknowledgements We thank Moctezuma Reimann and Patrick Zitzow for technical assistance. This study was supported by the EMIDA ERA-NET project “Molecular Epidemiology of Epizootic Diseases using Next Generation Sequencing Technology (Epi-SEQ)” (Grant 2811ERA094).

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflicts of interest.

References

1. Bintintan I, Meyers G (2010) A New type of signal peptidase cleavage site identified in an RNA virus polyprotein. *J Biol Chem* 285:8572–8584
2. Rümenapf T, Meyers G, Stark R, Thiel HJ (1991) Molecular characterization of hog cholera virus. *Arch Virol Suppl* 3:7–18
3. Lattwein E, Klemens O, Schwindt S, Becher P, Tautz N (2012) Pestivirus virion morphogenesis in the absence of uncleaved nonstructural protein 2-3. *J virol* 86:427–437
4. Meyers G, Thiel HJ (1996) Molecular characterization of pestiviruses. *Adv Virus Res* 47:53–118
5. Tratschin JD, Moser C, Ruggli N, Hofmann MA (1998) Classical swine fever virus leader proteinase N^{pro} Is not required for viral replication in cell culture. *J Virol* 72:7681–7684
6. Postel A, Schmeiser S, Perera CL, Rodriguez LJ, Frias-Lepoureau MT, Becher P (2013) Classical swine fever virus isolates

- from Cuba form a new subgenotype 1.4. *Vet Microbiol* 161:334–338
7. Greiser-Wilke I, Depner K, Fritzsche J, Haas L, Moennig V (1998) Application of a computer program for genetic typing of classical swine fever virus isolates from Germany. *J Virol Methods* 75:141–150
 8. Paton DJ, McGoldrick A, Greiser-Wilke I, Parchariyanon S, Song JY, Liou PP, Stadejek T, Lowings JP, Björklund H, Belák S (2000) Genetic typing of classical swine fever virus. *Vet Microbiol* 73:137–157
 9. Beer M, Goller KV, Staubach C, Blome S (2015) Genetic variability and distribution of Classical swine fever virus. *Anim Health Res Rev* 16:33–39
 10. Moennig V, Floegel-Niesmann G, Greiser-Wilke I (2003) Clinical signs and epidemiology of classical swine fever: a review of new knowledge. *Vet J* 165:11–20
 11. Dahle J, Liess B (1992) A review on classical swine fever infections in pigs: epizootiology, clinical disease and pathology. *Comp Immunol Microbiol Infect Dis* 15:203–211
 12. Munoz-Gonzalez S, Perez-Simo M, Munoz M, Bohorquez JA, Rosell R, Summerfield A, Domingo M, Ruggli N, Ganges L (2015) Efficacy of a live attenuated vaccine in classical swine fever virus postnatally persistently infected pigs. *Vet Res* 46:78
 13. Munoz-Gonzalez S, Ruggli N, Rosell R, Perez LJ, Frias-Leuporeau MT, Fraile L, Montoya M, Cordoba L, Domingo M, Ehrensperger F, Summerfield A, Ganges L (2015) Postnatal persistent infection with classical Swine Fever virus and its immunological implications. *PLoS One* 10:e0125692
 14. Hulst M, Loeffen W, Weesendorp E (2013) Pathway analysis in blood cells of pigs infected with classical swine fever virus: comparison of pigs that develop a chronic form of infection or recover. *Arch Virol* 158:325–339
 15. Collins ME, Desport M, Brownlie J (1999) Bovine viral diarrhoea virus quasispecies during persistent infection. *Virology* 259:85–98
 16. Dow N, Chernick A, Orsel K, van Marle G, van der Meer F (2015) Genetic variability of bovine viral diarrhoea virus and evidence for a possible genetic bottleneck during vertical transmission in persistently infected cattle. *PLoS One* 10:e0131972
 17. Ridpath JF, Bayles DO, Neill JD, Falkenberg SM, Bauermann FV, Holler L, Braun LJ, Young DB, Kane SE, Chase CC (2015) Comparison of the breadth and complexity of bovine viral diarrhoea (BVDV) populations circulating in 34 persistently infected cattle generated in one outbreak. *Virology* 485:297–304
 18. Petrov A, Blohm U, Beer M, Pietschmann J, Blome S (2014) Comparative analyses of host responses upon infection with moderately virulent classical swine fever virus in domestic pigs and wild boar. *Virol J* 11:134
 19. Gallei A, Blome S, Gilgenbach S, Tautz N, Moennig V, Becher P (2008) Cytopathogenicity of classical Swine Fever virus correlates with attenuation in the natural host. *J Virol* 82:9717–9729
 20. Blome S, Gabriel C, Schmeiser S, Meyer D, Meindl-Böhmer A, Koenen F, Beer M (2014) Efficacy of marker vaccine candidate CP7_E2alf against challenge with classical swine fever virus isolates of different genotypes. *Vet Microbiol* 169:8–17
 21. David D, Edri N, Yakobson BA, Bombarov V, King R, Davidson I, Pozzi P, Hadani Y, Bellaïche M, Schmeiser S, Perl S (2011) Emergence of classical swine fever virus in Israel in 2009. *Vet J* 190:e146–149
 22. Becker N, Jöst H, Ziegler U, Eiden M, Höper D, Emmerich P, Fichet-Calvet E, Ehichioya DU, Czajka C, Gabriel M, Hoffmann B, Beer M, Tenner-Racz K, Racz P, Günther S, Wink M, Bosch S, Konrad A, Pfeffer M, Groschup MH, Schmidt-Chanasit J (2012) Epizootic emergence of Usutu virus in wild and captive birds in Germany. *PLoS One* 7:e32604–e32604
 23. Juozapaitis M, Moreira É, Mena I, Giese S, Riegger D, Pohlmann A, Höper D, Zimmer G, Beer M, García-Sastre A, Schwemmler M (2014) An infectious bat-derived chimeric influenza virus harbouring the entry machinery of an influenza A virus. *Nat Commun* 5:4448
 24. Leifer I, Hoffmann B, Hoper D, Bruun Rasmussen T, Blome S, Strebelow G, Horeth-Bontgen D, Staubach C, Beer M (2010) Molecular epidemiology of current classical swine fever virus isolates of wild boar in Germany. *J General Virol* 91:2687–2697
 25. Katoh K, Misawa K, Kuma K, Miyata T (2002) MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform. *Nucleic Acids Res* 30:3059–3066
 26. Watson SJ, Welkers MR, Depledge DP, Coulter E, Breuer JM, de Jong MD, Kellam P (2013) Viral population analysis and minority-variant detection using short read next-generation sequencing. *Philos Trans R Soc Lond Ser B Biol Sci* 368:20120205
 27. Höper D, Freuling CM, Müller T, Hanke D, von Messling V, Duchow K, Beer M, Mettenleiter TC (2015) High definition viral vaccine strain identity and stability testing using full-genome population data—the next generation of vaccine quality control. *Vaccine* 33:5829–5837
 28. R Development Core Team (2014) R: a language and environment for statistical computing, 3.1.0 ed. R Foundation for Statistical Computing, Vienna, Austria
 29. Hulst MM, van Gennip HG, Moormann RJ (2000) Passage of classical swine fever virus in cultured swine kidney cells selects virus variants that bind to heparan sulfate due to a single amino acid change in envelope protein E^{ms}. *J Virol* 74:9553–9561
 30. Morelli MJ, Wright CF, Knowles NJ, Juleff N, Paton DJ, King DP, Haydon DT (2013) Evolution of foot-and-mouth disease virus intra-sample sequence diversity during serial transmission in bovine hosts. *Vet Res* 44:12
 31. Lange M, Kramer-Schadt S, Blome S, Beer M, Thulke HH (2012) Disease severity declines over time after a wild boar population has been affected by classical swine fever—legend or actual epidemiological process? *Prev Vet Med* 106:185–195
 32. Goller KV, Gabriel C, Le Dimna M, Le Potier M-F, Rossi S, Staubach C, Merboth M, Beer M, Blome S (2015) Evolution and molecular epidemiology of Classical swine fever virus during a multi-annual outbreak among European wild boar. *J General Virol* (**Epub ahead of print**)
 33. Dräger C, Beer M, Blome S (2015) Porcine complement regulatory protein CD46 and heparan sulfates are the major factors for classical swine fever virus attachment in vitro. *Arch Virol* 160:739–746
 34. Dräger C, Petrov A, Beer M, Teifke JP, Blome S (2015) Classical swine fever virus marker vaccine strain CP7_E2alf: Shedding and dissemination studies in boars. *Vaccine* 33:3100–3103
 35. Topfer A, Hoper D, Blome S, Beer M, Beerenwinkel N, Ruggli N, Leifer I (2013) Sequencing approach to analyze the role of quasispecies for classical swine fever. *Virology* 438:14–19
 36. Bordería AV, Isakov O, Moratorio G, Henningsson R, Agüera-González S, Organtini L, Gnädig NF, Blanc H, Alcover A, Hafenstein S, Fontes M, Shomron N, Vignuzzi M (2015) Group selection and contribution of minority variants during virus adaptation determines virus fitness and phenotype. *PLoS Pathog* 11:e1004838
 37. Fahnøe U, Pedersen AG, Dräger C, Orton RJ, Blome S, Höper D, Beer M, Rasmussen TB (2015) Creation of functional viruses from non-functional cDNA clones obtained from an RNA virus population by the use of ancestral reconstruction. *PLoS One* 10:e0140912
 38. Fahnøe U, Pedersen AG, Risager PC, Nielsen J, Belsham GJ, Höper D, Beer M, Rasmussen TB (2014) Rescue of the highly virulent classical swine fever virus strain “Koslov” from cloned cDNA and first insights into genome variations relevant for virulence. *Virology* 468–470:379–387